Zealand Pharma A/S Corporate Call Transcript
Good day, and thank you for standing by. Welcome to the conference call to discuss positive results from Phase III trial of Glepaglutide in patients with Short Bowel Syndrome. (Operator Instructions) Please be advised that today's conference is being recorded.
I would now like to hand the conference over to your speaker today, Anna Krassowska. Please go ahead.
/-&
Thank you. Welcome, everyone, and thank you for joining us today. I'm Anna Krassowska, Vice President of Investor Relations and Corporate Communications at Zealand. With me today to discuss Zealand's top line results for the Phase III EASE 1 trial of Glepaglutide in patients with Short Bowel Syndrome are Adam Steensberg, Zealand's President and Chief Executive Officer; and David Kendall, Zealand's Chief Medical Officer.
You can find the related company announcement on our website at zealandpharma.com. I would like to point out that we will be making forward
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |